Skip to main content

Table 3 Adverse events reported in all patients by CTP at time of event

From: Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans

CTP at time of AE GC MTX IL-1 Inhibitor IL-6 Inhibitor Total
Grade 2 0 2 (allergic reaction [1], arthritis flare [1]) 5 (MAS [1], hepatitis [1], rash [1], Strep pharyngitis [1], injection site reaction [1]) 8 (fever [1}, rash [1], arthritis flare [2], headache [1], neutropenia [1], viral illness [1], infusion reaction [1]) 15
Grade 3 0 0 2 (infections)b 0 2
Grade 4 0 0 0 1 (infusion reaction) 1
SAE 0 1a 2 (infections)b 1 (MAS) 3
  1. aAppendicitis and appendectomy
  2. b1 varicella (anakinra), 1 cellullitis (canakinumab)